2 results
Approved WMORecruitment started
To determine whether KJD is non-inferior on patient reported effectiveness as compared to a KP (i.e. usual care) for relatively young patients with end-stage knee OA. For the substudy: the primary objective is to predict the benefit from knee…
Approved WMORecruitment started
In the RAINBO POLEmut-BLUE trial, omission of adjuvant therapy will be investigated in very low risk disease and de-escalation of treatment (observation or radiotherapy, but not chemoradiation) in low risk disease.